Document is current

Any future updates will be listed below

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)

Crossref DOI link: https://doi.org/10.1186/s12883-015-0354-9

Published Online: 2015-06-23

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark